Skip to content

Structure Therapeutics

US · GPCR #2815 by market cap Listed 2023
26.68 -0.79 -2.88%
Live - 5344 symbols - heartbeat 93s ago · 2026-10-08 08:29
Pre-market 26.71 +0.11%
After-hours 27.00 +1.20%
Overnight 26.78 +0.37%
Market cap
1.90B
P/B
1.40
EPS
-2.40
Reader sentiment Are you bullish or bearish on GPCR?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Cuts Target Price to $70
    Market Newswire · 2026/6/11
  • Rating change
    Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $101
    Market Newswire · 2026/6/8
  • Company notice
    SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL SIGNS COOPERATION AGREEMENT WITH U.S.-BASED ABALONE BIO TO JOINTLY DEVELOP A NEW-GENERATION INNOVATIVE THERAPY FOR WEIGHT LOSS AND MUSCLE GAIN, FURTHER DEEPENING ITS LAYOUT IN THE GPCR TARGET FIELD
    HKEX · 2025/10/30
  • Rating change
    A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $111
    Market Newswire · 2026/8/8
  • Rating change
    William Blair Maintains Structure Therapeutics(GPCR.US) With Buy Rating
    Market Newswire · 2026/6/8
  • Rating change
    Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $126
    Market Newswire · 2026/8/10
  • Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
    TipRanks · 2026/9/9
  • CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $111
    Market Newswire · 2026/9/9
  • H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/9/9
  • Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)
    TipRanks · 2026/9/9
  • Rating change
    Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
    TipRanks · 2026/8/10
  • Rating change
    Citi Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $97
    Market Newswire · 2026/8/10
  • Rating change
    J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100
    Market Newswire · 2026/8/17
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: EnGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
    TipRanks · 2026/9/9
  • Rating change
    J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating
    Market Newswire · 2026/6/9
  • Rating change
    A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $97 to $145
    Market Newswire · 2026/8/7
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
    TipRanks · 2026/6/8
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Cabaletta Bio (CABA) and Hinge Health, Inc. Class A (HNGE)
    TipRanks · 2026/6/8
  • A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $125
    Market Newswire · 2026/9/9
  • Rating change
    Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
    TipRanks · 2026/8/8

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:29:49 · For reference only, not investment advice and not tailored to your situation.